CTLA4 and neoplasm: Given the variability of the responses to anti–CTLA-4 antibody therapy, we aimed to analyze the biological responses associated with “responders” and “nonresponders” (responders: tumor growth inhibition rate above median, nonresponders: tumor growth inhibition rate below median, median = 72.3%).